ALKS : Summary for Alkermes plc - Ordinary Shares - Yahoo Finance

U.S. Markets closed

Alkermes plc (ALKS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.57-0.98 (-1.76%)
At close: 4:00PM EST
People also watch
ALXNINCYBMRNNBIXVRTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close55.55
Open55.03
Bid49.52 x 1300
Ask55.59 x 200
Day's Range54.01 - 55.62
52 Week Range27.14 - 60.74
Volume734,272
Avg. Volume814,891
Market Cap8.29B
Beta2.33
PE Ratio (TTM)-32.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
    Capital Cube2 days ago

    Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017

    Categories: Yahoo Finance Get free summary analysis Alkermes Plc reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Alkermes Plc – Acorda Therapeutics, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Novartis AG Sponsored ADR and ... Read more (Read more...)

  • Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
    Zacks3 days ago

    Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat

    Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.

  • Alkermes' Revenue Soars, Projects an Exciting Year Ahead
    Motley Fool4 days ago

    Alkermes' Revenue Soars, Projects an Exciting Year Ahead

    The biopharma posted strong quarterly revenue growth and provided investors with reasons to remain optimistic about 2017.